Healthcare Professionals
Take the right treatment path.
HE4 test has been cleared by the
US Food and Drug Administration
for use as an aid in monitoring recurrence or progressive disease
in patients with epithelial ovarian cancer. Learn more>>
Ovarian cancer is not the silent killer it was once thought to be. Studies have shown that there are symptoms that appear in the early stages of the disease. Recognition of these symptoms in the early stages is critical. Currently, less than 20% of cases are diagnosed in the early stages, and the 5-year survival rate is 20% to 30% when diagnosed at stage III or IV, but when diagnosed in the early stages the probability of cure increases to 90% to 95%.7
Although there is not currently a screening test available for ovarian cancer, CA125™ is the gold-standard test in the management of this disease. Its use in monitoring treatment response and detecting recurrence has been tested for more than 20 years. The information that a CA125 test provides, combined with other procedures, affords additional time for patients to receive therapy and benefit from their treatment.12
